Back
Vericel Corp. 10K Form
Buy
51
VCEL
Vericel Corp.
Last Price:
$36.67
Seasonality Move:
28.78%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2023-11-08 | 10Q | VCEL/Vericel Corp. Quarterly |
| 2023-08-02 | 10Q | VCEL/Vericel Corp. Quarterly |
| 2023-05-10 | 10Q | VCEL/Vericel Corp. Quarterly |
| 2022-11-09 | 10Q | VCEL/Vericel Corp. Quarterly |
| 2022-08-03 | 10Q | VCEL/Vericel Corp. Quarterly |
| 2022-05-04 | 10Q | VCEL/Vericel Corp. Quarterly |
Receive VCEL News And Ratings
See the #1 stock for the next 7 days that we like better than VCEL
VCEL Financial Statistics
Sales & Book Value
| Annual Sales: | $237.2M |
|---|---|
| Cash Flow: | $19.5M |
| Price / Cash Flow: | 91.63 |
| Annual Sales: | $6.37 |
| Price / Book: | 5.74 |
Profitability
| EPS (TTM): | 0.24080 |
|---|---|
| Net Income (TTM): | $13.1M |
| Gross Margin: | $172.1M |
| Return on Equity: | 4.44% |
| Return on Assets: | 3.06% |
Vericel Corp. Earnings Forecast
Key Vericel Corp. Financial Ratios
-
The Gross Profit Margin over the past 29 years for VCEL is 72.55%.
-
The Selling, General & Administrative Expenses for VCEL have been equal to 60.19% of Gross Profit Margin.
-
The Research & Development expenses have been 10.45% of Revenue.
-
The Interest Expense is 5.93% of Operating Income.
-
The Net Earning history of VCEL is 4.37% of Total Revenues.
-
Per Share Earnings over the last 29 years have been positive in 16 years.
Vericel Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | VCEL |
| CUSIP: | 92346J |
| Website: | vcel.com |
Debt
| Debt-to-Equity Ratio: | 0.31 |
|---|---|
| Current Ratio: | 4.87 |
| Quick Ratio: | 4.3 |
Price-to-Earnings
| Trailing P/E Ratio: | 182.24 |
|---|---|
| Forward P/E Ratio: | 63 |
VCEL Technical Analysis vs Fundamental Analysis
Buy
51
Vericel Corp. (VCEL)
is a Buy
Is Vericel Corp. a Buy or a Sell?
-
Vericel Corp. stock is rated a BuyThe current Vericel Corp. [VCEL] share price is $36.54. The Score for VCEL is 51, which is 2% above its historic median score of 50, and infers lower risk than normal.